Deborah J Del Junco1, Eileen M Bulger2, Erin E Fox3, John B Holcomb3, Karen J Brasel4, David B Hoyt5, James J Grady6, Sarah Duran3, Patricia Klotz2, Michael A Dubick7, Charles E Wade3. 1. University of Texas Health Science Center, Department of Surgery, Houston, TX, United States. Electronic address: deborah.j.deljunco@uth.tmc.edu. 2. University of Washington, Department of Surgery, Seattle, WA, United States. 3. University of Texas Health Science Center, Department of Surgery, Houston, TX, United States. 4. Oregon Health & Science University, Department of Surgery, Portland, OR, United States. 5. American College of Surgeons, Chicago, IL, United States. 6. University of Connecticut Health Center, Institute for Clinical and Translational Science, Farmington, CT, United States. 7. U.S. Army Institute of Surgical Research, San Antonio, TX, United States.
Abstract
BACKGROUND: Collider bias, or stratifying data by a covariate consequence rather than cause (confounder) of treatment and outcome, plagues randomised and observational trauma research. Of the seven trials of prehospital hypertonic saline in dextran (HSD) that have been evaluated in systematic reviews, none found an overall between-group difference in survival, but four reported significant subgroup effects. We hypothesised that an avoidable type of collider bias often introduced inadvertently into trauma comparative effectiveness research could explain the incongruous findings. METHODS: The two most recent HSD trials, a single-site pilot and a multi-site pivotal study, provided data for a secondary analysis to more closely examine the potential for collider bias. The two trials had followed the a priori statistical analysis plan to subgroup patients by a post-randomisation covariate and well-established surrogate for bleeding severity, massive transfusion (MT), ≥ 10 unit of red blood cells within 24h of admission. Despite favourable HSD effects in the MT subgroup, opposite effects in the non-transfused subgroup halted the pivotal trial early. In addition to analyzing the data from the two trials, we constructed causal diagrams and performed a meta-analysis of the results from all seven trials to assess the extent to which collider bias could explain null overall effects with subgroup heterogeneity. RESULTS: As in previous trials, HSD induced significantly greater increases in systolic blood pressure (SBP) from prehospital to admission than control crystalloid (p=0.003). Proportionately more HSD than control decedents accrued in the non-transfused subgroup, but with paradoxically longer survival. Despite different study populations and a span of over 20 years across the seven trials, the reported mortality effects were consistently null, summary RR=0.99 (p=0.864, homogeneity p=0.709). CONCLUSIONS: HSD delayed blood transfusion by modifying standard triggers like SBP with no detectable effect on survival. The reported heterogeneous HSD effects in subgroups can be explained by collider bias that trauma researchers can avoid by improved covariate selection and data capture strategies.
BACKGROUND: Collider bias, or stratifying data by a covariate consequence rather than cause (confounder) of treatment and outcome, plagues randomised and observational trauma research. Of the seven trials of prehospital hypertonic saline in dextran (HSD) that have been evaluated in systematic reviews, none found an overall between-group difference in survival, but four reported significant subgroup effects. We hypothesised that an avoidable type of collider bias often introduced inadvertently into trauma comparative effectiveness research could explain the incongruous findings. METHODS: The two most recent HSD trials, a single-site pilot and a multi-site pivotal study, provided data for a secondary analysis to more closely examine the potential for collider bias. The two trials had followed the a priori statistical analysis plan to subgroup patients by a post-randomisation covariate and well-established surrogate for bleeding severity, massive transfusion (MT), ≥ 10 unit of red blood cells within 24h of admission. Despite favourable HSD effects in the MT subgroup, opposite effects in the non-transfused subgroup halted the pivotal trial early. In addition to analyzing the data from the two trials, we constructed causal diagrams and performed a meta-analysis of the results from all seven trials to assess the extent to which collider bias could explain null overall effects with subgroup heterogeneity. RESULTS: As in previous trials, HSD induced significantly greater increases in systolic blood pressure (SBP) from prehospital to admission than control crystalloid (p=0.003). Proportionately more HSD than control decedents accrued in the non-transfused subgroup, but with paradoxically longer survival. Despite different study populations and a span of over 20 years across the seven trials, the reported mortality effects were consistently null, summary RR=0.99 (p=0.864, homogeneity p=0.709). CONCLUSIONS:HSD delayed blood transfusion by modifying standard triggers like SBP with no detectable effect on survival. The reported heterogeneous HSD effects in subgroups can be explained by collider bias that trauma researchers can avoid by improved covariate selection and data capture strategies.
Authors: Biswadev Mitra; Peter A Cameron; Russell L Gruen; Alfredo Mori; Mark Fitzgerald; Alison Street Journal: Eur J Emerg Med Date: 2011-06 Impact factor: 2.799
Authors: Christopher W Snyder; Jordan A Weinberg; Gerald McGwin; Sherry M Melton; Richard L George; Donald A Reiff; James M Cross; Jennifer Hubbard-Brown; Loring W Rue; Jeffrey D Kerby Journal: J Trauma Date: 2009-02
Authors: Jing Ning; Mohammad H Rahbar; Sangbum Choi; Jin Piao; Chuan Hong; Deborah J Del Junco; Elaheh Rahbar; Erin E Fox; John B Holcomb; Mei-Cheng Wang Journal: Stat Methods Med Res Date: 2015-07-09 Impact factor: 3.021
Authors: Jing Ning; Mohammad H Rahbar; Sangbum Choi; Chuan Hong; Jin Piao; Deborah J del Junco; Erin E Fox; Elaheh Rahbar; John B Holcomb Journal: Stat Med Date: 2015-08-09 Impact factor: 2.373
Authors: Sangbum Choi; Mohammad H Rahbar; Jing Ning; Deborah J Del Junco; Elaheh Rahbar; Chuan Hong; Jin Piao; Erin E Fox; John B Holcomb Journal: J Clin Epidemiol Date: 2016-04-29 Impact factor: 6.437
Authors: Philip C Spinella; Nahed El Kassar; Andrew P Cap; Andrei L Kindzelski; Christopher S Almond; Alan Barkun; Terry B Gernsheimer; Joshua N Goldstein; John B Holcomb; Alfonso Iorio; Dennis M Jensen; Nigel S Key; Jerrold H Levy; Stephan A Mayer; Ernest E Moore; Simon J Stanworth; Roger J Lewis; Marie E Steiner Journal: J Trauma Acute Care Surg Date: 2021-08-01 Impact factor: 3.697
Authors: Nena Matijevic; Yao-Wei W Wang; John B Holcomb; Rosemary Kozar; Jessica C Cardenas; Charles E Wade Journal: J Extracell Vesicles Date: 2015-12-17
Authors: I E Blanchard; A Ahmad; K L Tang; P E Ronksley; D Lorenzetti; G Lazarenko; E S Lang; C J Doig; H T Stelfox Journal: BMC Emerg Med Date: 2017-11-28
Authors: Stacy A Shackelford; Deborah J Del Junco; Nicole Powell-Dunford; Edward L Mazuchowski; Jeffrey T Howard; Russ S Kotwal; Jennifer Gurney; Frank K Butler; Kirby Gross; Zsolt T Stockinger Journal: JAMA Date: 2017-10-24 Impact factor: 56.272
Authors: AlleaBelle Gongola; Jace C Bradshaw; Jing Jin; Hanna K Jensen; Avi Bhavaraju; Joseph Margolick; Kevin W Sexton; Ronald Robertson; Kyle J Kalkwarf Journal: Trauma Surg Acute Care Open Date: 2021-06-15